Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis

被引：0
|
作者：
Quan Rao
Min Li
Wei Xu
Kai Pang
XiaoBo Guo
Dong Wang
Jun Liu
Wei Guo
ZhongTao Zhang
机构：
[1] Capital Medical University,Department of General Surgery, Beijing Friendship Hospital
[2] Beijing Key Laboratory of Cancer Invasion and Metastasis Research and National Clinical Research Center for Digestive Diseases,Clinical Epidemiology and EBM Unit, National Clinical Research Center for Digestive Disease, Beijing Friendship Hospital
[3] Capital Medical University,Department of Vascular Surgery, Beijing Friendship Hospital
[4] Capital Medical University,undefined
来源：
Hepatology International | 2020年 / 14卷
关键词：
PD-1; PD-L1; Monoclonal antibody; Nivolumab; Pembrolizumab; Anti-VEGF agent; Objective response rate; Disease control rate; Overall survival; Progression-free survival; Adverse event; Meta-analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：765 / 775
页数：10
相关论文
共 50 条
  • [1] Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis
    Rao, Quan
    Li, Min
    Xu, Wei
    Pang, Kai
    Guo, XiaoBo
    Wang, Dong
    Liu, Jun
    Guo, Wei
    Zhang, ZhongTao
    [J]. HEPATOLOGY INTERNATIONAL, 2020, 14 (05) : 765 - 775
  • [2] Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis
    Wen, Wen
    Zhang, Yong
    Zhang, Hua
    Chen, Yingshuang
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (03) : 969 - 978
  • [3] Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis
    Wen Wen
    Yong Zhang
    Hua Zhang
    Yingshuang Chen
    [J]. Journal of Cancer Research and Clinical Oncology, 2023, 149 : 969 - 978
  • [4] Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis
    Yuwei Liu
    Jiahui Pan
    Fangbo Gao
    Wentao Xu
    Hongyu Li
    Xingshun Qi
    [J]. Advances in Therapy, 2023, 40 : 521 - 549
  • [5] Efficacy and Safety of PD-1/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis
    Liu, Yuwei
    Pan, Jiahui
    Gao, Fangbo
    Xu, Wentao
    Li, Hongyu
    Qi, Xingshun
    [J]. ADVANCES IN THERAPY, 2023, 40 (02) : 521 - 549
  • [6] The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors: A systematic review and meta-analysis
    Yang, Yao
    Chen, Dongbo
    Zhao, Bigeng
    Ren, Liying
    Huang, Rui
    Feng, Bo
    Chen, Hongsong
    [J]. CANCER MEDICINE, 2023, 12 (08): : 9282 - 9292
  • [7] Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis
    Xiao Zhang
    Zhengyang Yang
    Yongbo An
    Yishan Liu
    Qi Wei
    Fengming Xu
    Hongwei Yao
    Zhongtao Zhang
    [J]. World Journal of Surgical Oncology, 20
  • [8] Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis
    Zhang, Xiao
    Yang, Zhengyang
    An, Yongbo
    Liu, Yishan
    Wei, Qi
    Xu, Fengming
    Yao, Hongwei
    Zhang, Zhongtao
    [J]. WORLD JOURNAL OF SURGICAL ONCOLOGY, 2022, 20 (01)
  • [9] Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors in the treatment of hepatocellular carcinoma: A meta-analysis and systematic review
    Zhang, Baoyan
    Su, Linfeng
    Lin, Yonghua
    [J]. ONCOLOGY LETTERS, 2024, 28 (01)
  • [10] Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis
    Chen, Shixue
    Zhang, Zhibo
    Zheng, Xuan
    Tao, Haitao
    Zhang, Sujie
    Ma, Junxun
    Liu, Zhefeng
    Wang, Jinliang
    Qian, Yuanyu
    Cui, Pengfei
    Huang, Di
    Huang, Ziwei
    Wu, Zhaozhen
    Hu, Yi
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
12345